Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Trial details
- Registry ID
- NCT04802837
- Phase
- Phase 3
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Vancomycin oral
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837 | Summit Therapeutics | Phase 3 | Terminated | 2021-09-17Actual |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | ACXP | Phase 2 | Completed | 2023-10-03Actual |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |